JP2008528033A - ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 - Google Patents

ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 Download PDF

Info

Publication number
JP2008528033A
JP2008528033A JP2007553266A JP2007553266A JP2008528033A JP 2008528033 A JP2008528033 A JP 2008528033A JP 2007553266 A JP2007553266 A JP 2007553266A JP 2007553266 A JP2007553266 A JP 2007553266A JP 2008528033 A JP2008528033 A JP 2008528033A
Authority
JP
Japan
Prior art keywords
protein
polypeptide
precursor
sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007553266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528033A5 (enExample
Inventor
ローバート フォーガン ヘイレンベック,
エリザベス ボッシュ,
トーマス リンネマン,
アーネスティン リー,
Original Assignee
ファイブ プライム セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイブ プライム セラピューティクス, インコーポレイテッド filed Critical ファイブ プライム セラピューティクス, インコーポレイテッド
Publication of JP2008528033A publication Critical patent/JP2008528033A/ja
Publication of JP2008528033A5 publication Critical patent/JP2008528033A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2007553266A 2005-01-27 2006-01-27 ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 Pending JP2008528033A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64701305P 2005-01-27 2005-01-27
PCT/US2006/002951 WO2006081430A2 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009009381A Division JP2009131268A (ja) 2005-01-27 2009-01-19 ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法

Publications (2)

Publication Number Publication Date
JP2008528033A true JP2008528033A (ja) 2008-07-31
JP2008528033A5 JP2008528033A5 (enExample) 2009-03-05

Family

ID=36741080

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007553266A Pending JP2008528033A (ja) 2005-01-27 2006-01-27 ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法
JP2009009381A Pending JP2009131268A (ja) 2005-01-27 2009-01-19 ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009009381A Pending JP2009131268A (ja) 2005-01-27 2009-01-19 ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法

Country Status (9)

Country Link
US (1) US20080286834A1 (enExample)
EP (1) EP1841874B1 (enExample)
JP (2) JP2008528033A (enExample)
AT (1) ATE454455T1 (enExample)
AU (1) AU2006207999A1 (enExample)
CA (1) CA2589895A1 (enExample)
DE (1) DE602006011574D1 (enExample)
DK (1) DK1841874T3 (enExample)
WO (1) WO2006081430A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
JP5376948B2 (ja) 2005-09-13 2013-12-25 ナショナル リサーチ カウンシル オブ カナダ 腫瘍細胞活性を調節する方法及び組成物
US9060961B2 (en) * 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2009056330A1 (en) * 2007-10-31 2009-05-07 Eth Zurich Soluble truncated apom proteins and medical uses thereof
EP2271358B1 (en) * 2008-03-25 2018-11-21 Amarantus Therapeutics, Inc. use of mesencephalic astrocyte-derived neurotrophic factor for treating Parkinson's disease
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
RU2509774C2 (ru) 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
US8470554B2 (en) * 2008-12-22 2013-06-25 St. Jude Children's Research Hospital Prokaryotic expression of soluble, active Dkk
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4
US8614183B2 (en) 2009-11-13 2013-12-24 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
WO2011063523A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
AU2011248083B2 (en) 2010-05-04 2015-09-10 Five Prime Therapeutics, Inc. Antibodies that bind CSF1R
US8431532B2 (en) 2010-06-28 2013-04-30 Five Prime Therepeutics, Inc. FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
NZ703786A (en) 2010-11-15 2016-08-26 Five Prime Therapeutics Inc Fgfr1 extracellular domain combination therapies
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
WO2012097238A2 (en) 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
CN107823630A (zh) 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
HK1208233A1 (en) 2012-05-11 2016-02-26 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
MX2014015041A (es) 2012-06-08 2015-06-17 Shire Human Genetic Therapies Administración pulmonar de arnm a células objetivo no pulmonares.
EP2890398A4 (en) 2012-08-31 2016-03-09 Five Prime Therapeutics Inc METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R)
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
EP3431592A1 (en) 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
PE20160190A1 (es) 2013-08-01 2016-04-28 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9765147B2 (en) 2014-10-29 2017-09-19 Five Prime Therapeutics, Inc. Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
CN107257806B (zh) 2014-12-22 2021-08-10 戊瑞治疗有限公司 用于治疗pvns的抗csf1r抗体
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
LT3283527T (lt) 2015-04-13 2021-03-25 Five Prime Therapeutics, Inc. Kompleksinė terapija vėžio gydymui
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
EP3448414B1 (en) 2016-04-25 2024-04-17 Five Prime Therapeutics, Inc. Nope for treatment of pathological muscle loss and weakness
TWI781120B (zh) 2016-11-02 2022-10-21 美商永斯醫療股份有限公司 Pd-1之抗體及其用途
CN109906030B (zh) 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
US20190330376A1 (en) * 2016-12-29 2019-10-31 Development Center For Biotechnology Peptides derived from kininogen-1 for protein drugs in vivo half-life extensions
WO2018183608A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
EP3634988A4 (en) 2017-06-06 2021-02-24 Kindred Biosciences, Inc. ERYTHROPOIETIN AND SIMILAR COMPOUNDS FOR VETERINARY USE
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス, インク. Lilrb2に対する抗体
AU2019302454A1 (en) 2018-07-09 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to ILT4
WO2020146857A1 (en) * 2019-01-11 2020-07-16 Arbele Limited Multispecific prochemokine therapeutic proteins (park) and method of making and using thereof
WO2021178001A1 (en) * 2020-03-05 2021-09-10 Curie Co. Inc. Methods for cell free protein expression of mature polypeptides derived from zymogens and proproteins
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
CN116724051A (zh) 2020-08-10 2023-09-08 上海寻百会生物技术有限公司 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039529A1 (en) * 1995-06-06 1996-12-12 Basf Ag Compositions for expression of proteins in host cells using a preprocollagen signal sequence

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105508B1 (en) * 1998-08-17 2002-09-04 Europäisches Laboratorium Für Molekularbiologie (Embl) Method for purifying biomolecule or protein complexes
WO2005082934A2 (en) * 2004-02-20 2005-09-09 Five Prime Therapeutics, Inc. Novel apo2l and il-24 polypeptides, polynucleotides, and methods of their use
US20070264277A1 (en) * 2004-07-22 2007-11-15 Dirk Behrens Compositions and Methods of Use for Mgd-Csf in Disease Treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039529A1 (en) * 1995-06-06 1996-12-12 Basf Ag Compositions for expression of proteins in host cells using a preprocollagen signal sequence

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター

Also Published As

Publication number Publication date
WO2006081430A3 (en) 2007-04-05
DK1841874T3 (da) 2010-05-17
DE602006011574D1 (de) 2010-02-25
ATE454455T1 (de) 2010-01-15
CA2589895A1 (en) 2006-08-03
EP1841874B1 (en) 2010-01-06
AU2006207999A1 (en) 2006-08-03
EP1841874A2 (en) 2007-10-10
JP2009131268A (ja) 2009-06-18
WO2006081430A9 (en) 2006-11-30
US20080286834A1 (en) 2008-11-20
WO2006081430A2 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
JP2008528033A (ja) ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法
JP4860702B2 (ja) ポリペプチドのリコンビナント発現のための方法
KR101526019B1 (ko) 증대된 단백질 발현 및 정제를 위한 방법 및 조성물
JP6471175B2 (ja) 高効率分泌能を有するタンパク質分泌因子及びこれを含む発現ベクター
CN108610398B (zh) 一段功能序列及在分泌蛋白表达中的应用
JPH0541982A (ja) アミド酵素発現のための宿主および発現ベクタ
AU2016227621B2 (en) System for the presentation of peptides on the cell surface
Goth et al. Chemokine binding to PSGL-1 is controlled by O-glycosylation and tyrosine sulfation
JP2025081661A (ja) タンパク質発現のためのシステムおよび方法
JPWO2018074498A1 (ja) リムルス属由来の組換え蛋白質及びこれをコードするdna
TW201815818A (zh) 細胞相關之分泌增強融合蛋白
CN112592388A (zh) 一种2a肽、双顺反子表达载体、重组蛋白表达系统及应用
CN109666699B (zh) 一种基于lag-3/mhc ii阻断功能及其生物效应的药物快速筛选方法
JP4604184B2 (ja) 新規糖鎖認識蛋白質及びその遺伝子
JP2009502117A (ja) 赤血球新生刺激タンパク質生成のための組み換え法
JP2018515126A (ja) 抗原提示タンパク質と関連する方法及び組成物
JP2004520056A (ja) 可溶性ssaoの精製のための方法
JP2022518144A (ja) 高多様性ペプチドライブラリーを生成する方法およびタンパク質折り畳みを促進する方法
CN103717743A (zh) pAVEC
EP4305186A2 (en) Affinity agents
EP1352060A2 (en) Methods for expressing endogenous genes by restriction enzyme mediated integration
US20230212237A1 (en) Methods for producing proteins
WO2020139855A2 (en) Chimeric signal peptides for protein production
HK40008758A (en) Improved method for selecting polypeptide producing cells
HK40008758B (en) Improved method for selecting polypeptide producing cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111003

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120306